Cytokine gene polymorphisms modify expression and their circulating protein levels reflect inflammatory response. Chronic inflammation plays a key role in the pathogenesis of colorectal neoplasia (CRN) associated with inflammatory bowel disease, but it is not clear whether inflammation is a cause or an effect of tumours in sporadic CRN. We therefore investigated the association of cytokine gene polymorphisms and circulating cytokine levels on the risk of CRN in Northeast Scotland, which has a high incidence of CRN. We recruited two groups of patients from a screening colonoscopy cohort, either preprocedure or 3-24 months postprocedure. Participants with CRN were compared with participants with no evidence of CRN (controls). Bloodderived DNA was used to genotype polymorphisms in IL1B, IL1-RN, IL6, IL8, IL10, PTGS2 and TNFA genes. Circulating levels of high-sensitivity C-reactive protein and six cytokines [interleukin-1β (IL-1β), IL-4, IL-6, IL-8, IL-10 and tumour necrosis factor-α (TNF-α)] were measured. To examine the effect of CRN resection on marker levels, we used propensity score matching. A total of 884 patients were eligible for analysis, including 388 CRN cases and 496 controls. Cases were older (mean age 64 vs. 62 years, P < 0.01) and more likely to be men (67 vs. 55%, P < 0.001). Controls were more likely to be regular users of NSAID (P < 0.0001). Compared with homozygous carriage of respective common alleles, proinflammatory CC genotypes of IL1B-31C > T [odds ratio (OR) (95% confidence interval (CI) 1.68 (1.03-2.73)] and PTGS2-765 C > G [OR (95% CI) 2.97 (1.05-8.46)] were each associated with an increased risk of CRN. Conversely, carriage of the A allele of IL8-251A > T was associated with a lower risk of CRN compared with the TT genotype [ORs (95% CI) 0.60 (0.41-0.86) for heterozygous, 0.88 (0.57-1.37) for homozygous, and 0.68 (0.48-0.95) for heterozygous and homozygous combined]. Compared with postprocedure cases, IL8, TNF-α and C-reactive protein levels were significantly higher in preprocedure cases, but IL4 and IL10 protein levels were significantly lower. Proinflammatory cytokine gene polymorphisms in IL1B-31 and PTGS2-765 increase the risk of developing CRN. Levels of proinflammatory IL8, TNF-α and C-reactive protein markers are significantly higher while CRN is in situ. Along with the NSAID findings, these data point to inflammation as an underlying pathogenetic mechanism in CRN.
Introduction
Colorectal cancer (CRC) is a leading cause of death and the third most common cancer worldwide, with an estimated 1.23 million new cases diagnosed in 2008 (Ferlay et al., 2010) . Chronic inflammation has been implicated as a cause of many types of cancer on the basis of experimental, epidemiological and clinical evidence. Inflammation is a complex, highly orchestrated process involving many cell types and molecules, some of which drive the process, some modulate it and a number that do both at different points (Kushner and Rzewnicki, 1994) . Circulating levels of effector molecules and products, including acute-phase proteins such as C-reactive protein (CRP), may potentially be being biomarkers for colorectal neoplasis (CRN) as they are for other chronic diseases such as diabetes (Hu et al., 2004; Liu et al., 2007) . Several studies have investigated the association of circulating inflammatory marker levels and CRN, with inconsistent findings. Some studies have found positive associations of the risk of CRN with certain inflammatory markers (Otani et al., 2006; Chiu et al., 2008; Kim et al., 2008; Tsilidis et al., 2008a; Chan et al., 2011a; Prizment et al., 2011) , whereas others showed opposite (Ognjanovic et al., 2010; Gunter et al., 2006 Gunter et al., , 2011 or null associations (Kim et al., 2008; Tsilidis et al., 2008b; Chan et al., 2011a) . Single-nucleotide polymorphisms (SNPs) in the promoter regions of genes encoding these cytokines may influence changes in their expression and, potentially, the risk of cancer as a consequence. Many SNPs have been identified in the regulatory regions of cytokine genes, of which some have been associated with an increased risk of different types of cancers, including gastrointestinal cancers. (El-Omar et al., 2003; Landi et al., 2003; Camargo et al., 2006a; Tsilidis et al., 2009; Gunter et al., 2006 Gunter et al., , 2011 Li et al., 2011) . It has also been shown that some of these SNPs influence the response to antiinflammatory drugs that are potential chemopreventive agents against CRC (Macarthur et al., 2005; Ulrich et al., 2005; Sansbury et al., 2006) . Accordingly, we have investigated these associations in a CRC screening population of Northeast Scotland, which has one of the highest incidences of CRC in the UK.
The aims of our study were first to investigate the associations of polymorphisms in the ILIB, IL1RN, IL6, IL8, IL10 and TNFA genes with the risk of CRN, second to examine the associations of circulating levels of highsensitivity-CRP (Hs-CRP), interleukin-1β (IL1β), IL6, IL8, tumour necrosis factor-α (TNF-α), IL4 and IL10 with prevalent CRN, third to evaluate the effect of removal of CRN on circulating cytokine levels and finally to evaluate the interaction of genotype and aspirin/ NSAID use in the risk of CRN.
Materials and methods

Study population
Patients enrolled in the present study were recruited from a cohort of individuals who participated in the National Bowel Cancer Screening Programme (BCSP). The BCSP is a biennial, guaiac faecal occult blood test (FOBT) screening programme offered to an unselected population aged between 50 and 74 years. All FOBTpositive patients are offered a colonoscopy as the first choice of screening. The Northeast region of Scotland was one of the first areas in the UK to participate in the BCSP pilot, which started on 29 March 2000, conducted in the Northeast region of Scotland, which includes rural, suburban and urban areas with a diverse socioeconomic mix of mainly White populations. In the Scottish screening pilot, during the three rounds of screening, a total of 931 912 invitations were sent, and an evaluable result was obtained in 507 345, yielding an uptake of 54.4%. The proportion of those completing the test with a positive result requiring further investigation was 1.7%. The uptake for colonoscopy in those with a positive FOBT result was 85.4%. Histopathological examination of biopsies, polypectomy specimens and resection specimens was carried out by selected specialist consultant gastrointestinal pathologists using an agreed pro forma for reporting biopsies and polypectomy specimens. In the screened patients (507 345), the adenoma detection rate was 0.48% and cancer was diagnosed in 0.13%. Patients for the current study were identified from the Northeast of Scotland CRC screening database and approached to participate in the study.
Study objectives and design
This was a case-control study. The definition of a 'Case' was any patient with a histological diagnosis of an adenomatous polyp or colorectal carcinoma identified at screening colonoscopy. The 'Control' was any individual who had other diagnosis including haemorrhoids, diverticulosis, hyperplasic polyps or who had a completely normal colonoscopy. As inflammatory bowel disease (IBD) is associated with elevated inflammatory markers, which in turn could cause a bias during analysis, any patient with a diagnosis of IBD was excluded from the analyses.
Between 2008 and 2010, a total of 905 patients were recruited, of whom 21 patients were excluded because of the diagnosis of IBD. Among the 884 remaining patients, there were 388 CRN cases and 496 controls. Of the 496 controls, 299 individuals had a completely normal colonoscopy and 197 had other diagnoses including diverticular disease (n = 163) and hyperplastic polyps (n = 44) with some overlap. Cases were further classified as high risk CRN (n = 288) if they had a histological diagnosis of cancer or high grade dysplasia or tubovillous adenoma or at least three adenomas or adenoma of at least 1 cm diameter and low risk CRN (n = 100) if they had less than three adenomas all less than 1 cm diameter.
To investigate the association of the presence or absence of CRN with contemporaneous circulating levels of inflammatory markers, two groups of patients were recruited (Fig. 1) . The 'preprocedure' group included patients in whom the inflammatory markers were measured just before screening colonoscopy (i.e. when they still had the adenoma or cancer in situ) and the 'postprocedure' group included patients in whom the inflammatory markers were measured after removal of the neoplastic lesion within 3-24 months after screening colonoscopy. In the preprocedure group, a total of 561 patients were prospectively enrolled, of whom 242 were determined to be cases and 319 were controls. In the postprocedure group, a total of 323 patients were enrolled, including 146 previously detected cases and 177 controls (Fig. 1) . To compare preprocedure and postprocedure inflammatory marker levels among cases, we used propensity score matching to match preprocedure to postprocedure patients using their covariate characteristics. The propensity score method generates balanced subsamples in a synthetic experimental design, thus allowing comparison of preprocedure and postprocedure levels, even though measured on different individuals.
Demographic lifestyle data
At the time of recruitment, a research team member completed the clinical assessment record for every participant and collected data on age, sex, self-reported height and weight, central abdominal girth, medical conditions and medication use, gastrointestinal symptoms, smoking status (never/ever), alcohol use (any/ none), occupation and history of CRC in first-degree relatives. Daily use of aspirin and statins for more than 1 year or more than 5 years was recorded and analysed. Patients were considered as regular users of other NSAID if they consumed NSAID daily for more than 1 month. Dietary intake for each participant was assessed using a previously validated (Masson et al., 2003) Scottish Collaborative Group semiquantitative Food Frequency Questionnaire version 6.5, consisting of a list of 170 food items.
Laboratory methods
Blood inflammatory markers data
Fasting whole blood was collected at the time of recruitment for all patients, with serum and plasma isolated by centrifugation and stored at − 80°C. Serum Hs-CRP measurement was performed using the CardioPhase Hs-CRP assay (Dade Behring Inc., Newark, Delaware, USA) on the BN Systems, which measures Hs-CRP concentrations by particle enhanced immunonephelometry. The limit of detection of the assay was 0.175 mg/l for a sample dilution of 1 : 20 and the coefficient of variation was less than 10% for concentrations between 0.5 and 62 mg/l (BN Pro-spec System instruction manual).
Plasma was used at a 1 : 4 dilution to measure six cytokine levels (IL6, IL8, IL1B, TNF-α, IL4 and IL10) using the BD cytometric bead array Human soluble Protein Flex set system (Becton Dickinson Co., New Jersey, USA). For both the CRP and the cytokine measurements, all the samples were blinded and distributed randomly in analysis plates.
Genotyping data
Candidate SNPs were selected for evaluation on the basis of functional data indicating effects on expression and minimum 5% minor allele frequency in Caucasians. Genomic DNA was purified from 6 ml of whole blood using the Invitrogen Gene Catcher gDNA Kit (Invitrogen, Carlsbald, CA, USA) according to the manufacturer's protocol. Genotyping for allele specific detection of SNPs was performed using the TaqMan SNP genotyping assays, which use the 5′ nuclease assay chemistry for amplification and detection of specific SNP alleles in purified genomic DNA samples. The IL1B-31C > T, IL10-592 A > C, IL10-1082 A > G and TNFα-308 A > G have previously been genotyped successfully by our group and the results have been published (Macarthur et al., 2005) . Taqman assays for these SNPs were available off the shelf from Applied Biosystems (Foster City, California, USA). For the COX2-765 G > C (rs20417) and IL6-174 C > G (rs1800795) SNPs, Applied Biosystems did not have an off-the-shelf assays and custom assays were designed (Applied Biosystems custom design service; see Supplementary data, Table 6a ). For the penta-allelic IL1RN VNTR polymorphisms, DNA was amplified using primers flanking the 86 bp tandem repeats polymorphic region in intron 2. The primers were 5′ CTCAGCAACACTCCTAT 3′ (forward) and 5′TCCTGGTCTGCAGGTAA 3′ (reverse) (Tarlow et al., 1993) . The PCR was performed at 95°C for 5 min (35 cycles), 94°C for 1 min, 60°C for 1 min, 72°C for 1 min and the final step at 72°C for 10 min. PCR products were electrophoresed in a 2% agarose gel and visualized under ultra violet light after ethidium bromide staining. IL1RN alleles were coded as allele 1, four repeats, product size 450 bp; allele 2, two repeats, product size 270 bp; allele 3, five repeats, product size 530 bp; allele 4, three repeats, product size 360 bp; and allele 5, six repeats, product size 620 bp.
All the studied polymorphisms except for the IL1RN VNTR were confirmed by direct sequencing of PCR products of each genotype. The primers used for PCR and subsequent sequencing are shown in Supplementary data, Table 6b . For the COX2-765 G > C, the PCR products were sequenced following cloning into a PCR vector and using M13 sequence primers.
To ensure reproducibility of genotyping methods, multiple blinded quality control samples were embedded among the case-control samples and for all genotypes tested, the quality control samples indicated a reproducibility rate of 100% (data not shown). The genotyping success rate was greater than 98% for all the studied genes, except for TNF-308 G > A (94.4%). Among the patients who failed to be genotyped for TNF-308 G > A, there were no significant differences in distribution between cases (n = 27) and controls (n = 28). The genotype frequencies in the control group for all the selected SNPs were in Hardy-Weinberg equilibrium.
Statistical analyses
Statistical analyses were carried out using SAS, version 9.3 (SAS Inc., Cary, North Carolina, USA) software. Baseline characteristics, SNPs and serum inflammatory markers concentrations were evaluated by CRN status (i.e. any vs. none, high risk vs. low risk vs. none, and preprocedure vs. postprocedure) using the Wilcoxon rank-sum test for continuous variables and the χ 2 -test for categorical variables, and are shown as medians (interquartile ranges) and frequencies (percentages), respectively. In all analyses of the inflammatory marker SNPs, the homozygote of the more frequent allele was used as the referent category. For linear trend testing, the referent category was the more frequent allele that was scored on an ordinal scale as 0, the heterozygote was scored as 1 and the rare homozygote was scored as 2 (codominant model). For the dominant model, homozygous and heterozygous carriers of the less frequent allele were combined and scored as 1. Inflammatory markers were divided into two categories using medians on the basis of the distribution among the controls. Logistic regression models were used to estimate the odds ratios (OR) and the corresponding 95% confidence intervals (CIs) to compare cytokine gene polymorphism/median cytokine levels in cases versus controls separately for the preprocedure and postprocedure patients. To examine whether the effect of aspirin/NSAID use on the risk of CRN varies across strata of genotypes or cytokine levels, we assessed the interaction of aspirin/NSAID use, and genotype or cytokine levels by including cross product terms between aspirin/NSAID use, and genotype or cytokine levels. Polytomous logistic regression models were used to estimate the OR and 95% CIs for elevated cytokine levels in low-risk CRN and high-risk CRN compared with controls. To examine the effect of CRN removal, logistic regression was first used to calculate a propensity score, on the basis of age, sex, BMI, alcohol consumption, exercise, smoking, diverticular disease, exercise and aspirin use. To create the propensitymatched data set, 1 : 1 Greedy matching was used, restricted to preprocedure and postprocedure patients within the area of propensity score overlap. As recommended by Austin (2011) , a caliper of 0.2 SD of the logit of the propensity score was used to match the two groups. We assessed variable balance postmatching using the standardized difference method. To estimate the effect of CRN removal (i.e. polypectomy) on cytokine levels, median log marker levels preprocedure and postprocedure were compared using quantile regression models. This comparison was further validated in a subset of 23 patients for whom both preprocedure and postprocedure blood samples were available.
Ethical approval
Ethical approval for the study was granted by the North of Scotland Research ethics committee. All participants provided written informed consent.
Results
In unadjusted analyses, cases were older than controls and more likely to be men and to consume alcohol, but less likely to report using NSAID for more than a month (Table 1) . None of the cytokine polymorphisms significantly predicted CRN grade (data not shown).
Inflammatory marker levels and CRN risk
Associations between CRN and inflammatory marker levels are shown separately for the preprocedure and postprocedure patients (Tables 3 and 4 , respectively). In the preprocedure patients, none of the markers significantly predicted CRN overall, but CRP values above the median were associated significantly with low-grade polyps [OR (95% CI) 2.95 (1.22-7.15)] (Table 3 ). In the postprocedure group, none of the markers significantly predicted high-risk, low-risk or total CRN (Table 4) .
Of note, no significant interactions were detected between aspirin/NSAID use and cytokine polymorphisms. Similarly, among preprocedure patients, no interaction was detected between aspirin/NSAID use and cytokine levels. However, among postprocedure patients, we detected an interaction between IL6 levels and aspirin/NSAID use, such that compared with individuals with low IL6 levels, participants with high IL6 levels were at a higher risk of CRN (OR: 2.01, 95% CI: 1.13-3.58), among aspirin/NSAID nonusers, in contrast to aspirin/NSAID users who were not at risk of CRN (OR: 0.61, 95% CI: 0.28-1.31) (data not shown).
The variables used for propensity score prediction were well balanced between preprocedure and postprocedure matched groups such that all standardized differences were less than 0.1. Comparing levels of the inflammatory markers, IL8, TNF-α and CRP levels were significantly higher preprocedure versus postprocedure, whereas IL4 was significantly lower (Table 5) . In a sensitivity analysis of 23 patients who had both preprocedure and postprocedure samples, the results were of similar magnitude as well as in the same direction, although with limited statistical power most comparisons were not significant (Table 5) .
Discussion
More than half of the deaths because of CRC occur in developed countries (Ferlay et al., 2010) , where screening colonoscopy in the last decade has significantly reduced CRC mortality. A meta-analysis of randomized-controlled trials found that screened patients had a 16% reduction in the risk of mortality because of CRC (Hewitson et al., 2007) . Although this is encouraging, participation in screening still remains poor and hence the ultimate aim would be to develop preventive strategies against the development of this deadly condition. Chemoprevention of both CRC and its precursor lesions, adenomas, through long-term use of aspirin and other NSAIDs is shown to be effective in both hereditary and sporadic CRN. (Burn et al., 2011; Rothwell et al., 2011) . Although such results are encouraging, both nonspecific COX inhibitors, such as aspirin, and COX-2-specific inhibitors have significant gastrointestinal and cardiovascular toxicity that needs to be balanced against their demonstrated benefits (Menter et al., 2010) . To overcome this, identification of suitable 'at-risk' candidates for chemoprevention through the use of modern molecular profiling methods evaluating risk versus response pathways is essential. These methods, when combined with standard clinical risk profiles, will help in understanding how best to use aspirin/NSAIDs for cancer prevention by identifying patients most likely to benefit and/or excluding those individuals at the highest risk of significant toxicity (Menter et al., 2010) . Aspirin/NSAIDs act through attenuation of inflammation, which has been proposed to play a key role in the pathogenesis of CRN and is also the target for preventive strategies (Trinchieri, 2011) . Hence, we have investigated the associations of inflammatory marker levels and genetic polymorphisms with the risk of CRN.
Inflammatory gene polymorphisms and the risk of CRN
Although the IL1B-31 CC genotype has been shown previously to increase the risk of gastric cancer (El-Omar et al., 2000) , its association with CRN has been inconsistent. In a previous study by our group, there was no association of the IL1B-31C > T genotype with the risk of CRC in a Scottish population (Macarthur et al., 2005) . In contrast, a sigmoidoscopy-based case-control study found that heterozygosity at the IL1B-31C > T locus was associated with an increased risk of colorectal adenoma [OR 1.8 (95% CI) 1.8 (1.2-2.9)] (Gunter et al., 2006, 2011) . However, the authors were cautious in their interpretation of the latter study because the genotypes were not distributed in accordance with Hardy-Weinberg equilibrium and the possibility of false-positive reporting. Nevertheless, as that study and ours were carried out in screened populations in whom colorectal neoplasia is mostly detected at early stages (i.e. adenoma), these combined findings suggest that IL1B may be involved in the initiation of the neoplastic process.
Homozygosity of the less common C allele of the proinflammatory PTGS2-765 C > G SNP significantly increased the risk of CRN, reinforcing previous evidence implicating other PTGS2 polymorphisms. In a recent systematic review by Pereira et al., the PTGS2-899G > C and − 1329G > A polymorphisms increased the risk for CRC [ORs (95% CI) 1.35 (1.01-1.81) and 1.36 (1.11-1.66), respectively]. They also found in a pooled analysis that the 429T > C polymorphism was associated with an increased risk of adenoma, suggesting involvement in early carcinogenesis, although they acknowledged the inherent limitations of findings from a systematic review (Pereira et al., 2009) .
In contrast to the previous evidence, the A allele of IL8-251A > T SNP was associated with a significantly lower risk of CRN, although small numbers in these subgroup analyses suggest cautious interpretation. Conversely, a French study involving 1023 CRC cases and 1121 matched controls found that the IL8-251 AA genotype increased the risk of CRC (Küry et al., 2008) despite previous null (Theodoropoulos et al., 2006; Gunter et al., 2006 Gunter et al., , 2011 and opposite direction findings (Landi et al., 2003) .
We did not find any significant associations of CRN with the IL1RN VNTR polymorphism. Despite its wellestablished association with gastric cancer, not many studies have investigated associations with CRC. To our knowledge, only one study limited to 125 CRC cases and 134 controls has reported that the IL1RN VNTR polymorphism increases the risk of CRC (Viet et al., 2005) .
We did not find any significant association for the IL6-174 C > G polymorphism. The IL6-174 C > G polymorphism has been associated previously with CRC, with a large study involving 1579 CRC cases and 1977 controls showing that the G allele decreased risk (Slattery et al., 2007) and a smaller study showing that the C allele increased risk (Landi et al., 2003) . However, subsequent attempts at replication yielded null findings (Tsilidis et al., 2009; Cacev et al., 2010) .
For the IL10-1082 A > G and IL10-592 A > C SNPs, we did not observe any statistically significant associations, in agreement with some previous reports (Macarthur et al., 2005; Gunter et al., 2006 Gunter et al., , 2011 . However, another study found that the homozygous GG genotype at IL10-1082 was associated with a lower risk of CRC than homozygous AA [OR (95% CI) 0.58 (0.35-0.95)] (Tsilidis et al., 2009 ).
The role of TNFα-308A > G SNP has been studied widely in relation to gastric cancer, with a statistically significant increased risk associated with the AA genotype (Gorouhi et al., 2008) . Although many studies have investigated its association with CRC, so far, no study, including ours, has shown any significant association.
As replication is essential to establish the credibility of genotype-phenotype association studies (Chanock et al., 2007) , we acknowledge that all of the above findings need further evaluation in studies involving different populations and larger sample sizes before any firm conclusions can be made. It is also possible that our null findings for certain SNPs may be because of the lack of adequate statistical power. Another important aspect of genetic association studies of inflammation is that the inflammatory process is complex, involving multiple cytokines controlled by the genotype. It would be prudent to examine the effects of combinations of these polymorphisms on the risk of CRN.
Inflammatory marker levels and the risk of CRN
There is inconsistent finding in the literature for the association of inflammatory markers and CRN. The results from two prospective studies suggested that elevated IL-6 was associated with an increased risk of CRC (Heikkilä et al., 2008) . In the CLUE II cohort, Tsilidis et al. found that prediagnostic plasma CRP concentration was not associated with the risk of colorectal adenoma. The OR of colorectal adenoma among those in the highest quarter (>2.95 mg/l) of the CRP concentration compared with the lowest quarter (< 0.65 mg/l) was 0.61 (95% CI, 0.29-1.25; P for trend =0.25) (Tsilidis et al., 2008a (Tsilidis et al., , 2008b . In another study, there were no associations between serum levels of the inflammatory markers CRP and IL-6 and colorectal adenoma (Ognjanovic et al., 2010) .
We found elevated CRP levels before resection (preprocedure) of low-risk, but not high-risk, CRN. We found no associations after polypectomy (postprocedure) for low-risk, high-risk or total CRN. It has been suggested that some of the divergent results across studies of CRP may be related to sex differences (Chan et al., 2011b) . Our positive results should be viewed with caution in light of a recent study among women in the Nurses' Health Study that found no association of CRC with CRP or IL-6 level (Chan et al., 2011b) , consistent with several other studies that have not observed any significant associations of CRP and cancer (Ito et al., 2005; Siemes et al., 2006; Allin et al., 2009 Allin et al., , 2010 Heikkilä et al., 2009) . Furthermore, a nested case-control study of incident colorectal adenoma in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial found that a one unit increase in log CRP level was associated with a 15% reduction in the risk of developing colorectal adenoma [OR (95% CI) 0.85 (0.75-0.98), P trend 0.01)]. (Gunter et al., 2011) .
We did not observe any significant associations of circulating levels of IL6, IL8, TNF-α, IL1β, IL4 or IL10 with the risk of CRN in case-control analyses for both the preprocedure and the postprocedure groups.
In the small number of patients with both preprocedure and postprocedure samples, CRP levels decreased following polypectomy. One possible reason for this could be that the presence of CRN creates a proinflammatory milieu that results in an increase in the circulating levels of the inflammatory markers. Moreover, higher levels of prediagnostic CRP are associated with a poor prognosis postoperatively.
Using the propensity-matched data set, we also observed significant differences in circulating marker levels between preprocedure and postprocedure cases. Specifically, levels of the proinflammatory markers CRP, IL8 and TNF-α were significantly higher when the CRN was in situ (i.e. preprocedure) than after removal (i.e. postprocedure), whereas the anti-inflammatory markers IL4 and IL10 were significantly lower. Even though these are significant findings, one should be cautious in interpreting and drawing conclusions as the preprocedure and postprocedure measurements were from different patients. However, in light of these interesting observations, levels of inflammatory markers should be measured in a larger group of CRN patients before and after removal of their neoplastic lesions.
Our study suggests that the presence of CRN may increase levels of inflammatory markers, providing some insight into the possible sequence of events in the inflammation-cancer relationship. Replication of these findings and extension in larger studies could further define the role of inflammation in the pathogenesis of CRN. 
